JenaValve today announced the successful first cases and official U.S. commercial launch of its Trilogy heart valve system.

This marks the first dedicated transcatheter heart valve approved for high-risk patients with symptomatic severe AR.

Aortic insufficiency is a potentially severe condition that affects the heart’s ability to pump blood. There are many possible causes for this condition. Aortic insufficiency is a form of heart valve ...

PARIS -- The early commercial experience with transcatheter aortic valve replacement (TAVR or TAVI) for severe aortic regurgitation appeared promising, though device size issues and conduction ...

SAN FRANCISCO -- Aortic valve regurgitation treated with the investigational JenaValve Trilogy appeared safe and effective in the ALIGN AR trial. The device met the safety benchmark, with a 26.7% rate ...

Please provide your email address to receive an email when new articles are posted on . LAS VEGAS — A novel dicrotic notch index identified hemodynamically significant paravalvular aortic ...

Please provide your email address to receive an email when new articles are posted on . A novel transcatheter heart valve system may be suitable for patients with noncalcified aortic valve disease who ...

Background Transcatheter aortic valve replacement (TAVR) has already been recommended for some high-risk patients with aortic ...

SAN FRANCISCO — Among patients with symptomatic, severe native aortic regurgitation at high surgical risk, the JenaValve Trilogy transcatheter heart valve system (JenaValve Technology) met its primary ...

Atrial fibrillation (AF) was present in 1 in 6 patients with chronic aortic regurgitation — either moderate-to-severe or severe — and was independently associated with an increased risk for mortality ...

However, aortic regurgitation (AR) remains an "off-label" indication for TAVR, particularly for patients with mild or absent leaflet calcification or aortic annulus dimensions beyond the size of the ...

Background Transcatheter aortic valve replacement (TAVR) has increasingly emerged as one of the primary treatments for ...